Photo from wikipedia
Mutant isocitrate dehydrogenase 1/2 (mIDH1/2) proteins catalyze production of the oncometabolite D‐2‐hydroxyglutarate (2‐HG). Ivosidenib and enasidenib are oral inhibitors of mIDH1 and mIDH2, respectively. An open‐label phase 1 study is… Click to show full abstract
Mutant isocitrate dehydrogenase 1/2 (mIDH1/2) proteins catalyze production of the oncometabolite D‐2‐hydroxyglutarate (2‐HG). Ivosidenib and enasidenib are oral inhibitors of mIDH1 and mIDH2, respectively. An open‐label phase 1 study is evaluating the safety and efficacy of ivosidenib or enasidenib combined with intensive induction and consolidation chemotherapy in adult patients with newly diagnosed mIDH1/2 acute myeloid leukemia (AML; NCT02632708). In this population, we characterized the pharmacokinetics (PK), pharmacodynamics (PD), and PK/PD relationships for ivosidenib and enasidenib.
Journal Title: Clinical Pharmacology in Drug Development
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!